ThromboGenics Presenting Ocriplasmin Research Findings at Upcoming ASRS 2016 Annual Scientific Meeting in San Francisco

Leuven, Belgium, 3rd August, 2016 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on developing novel medicines for diseases of the retina, announces that further ocriplasmin clinical data will be presented at the 34th Annual Scientific Meeting of the American Society of Retina Specialists. The Meeting is being held from August, 9th through August 14th, 2016 in San Francisco, California.

Wednesday 10th August
12:55-1:35 PM Macular Surgery Symposium

12:55 ORBIT: A Phase IV Clinical Study: Lessons Learned From Patient Selection Criteria for Ocriplasmin Intravitreal Injection, by Mathew MacCumber, MD, PhD

1:35-1:55 PM Macular Surgery Symposium—Rapid Fire Papers

1:35 The OASIS Trial: Natural History of Symptomatic Vitreomacular Adhesion, by Joseph Coney, MD

1:40 The OASIS Trial: Efficacy and Safety Outcomes in Subjects With Full-Thickness Macular Hole, by Michael Tolentino, MD

The presentations will cover data from ORBIT, an ocriplasmin Phase IV clinical study, and from the OASIS randomized trial, a 2 year follow-up study evaluating Ocriplasmin for the treatment of symptomatic VMA (VMT) including macular hole.

Dr Patrik De Haes, CEO of ThromboGenics nv, comments, “We are delighted to have the opportunity to share our research at the American Society of Retina Specialists this year. ThromboGenics is committed to high-quality fundamental research in the field of ophthalmology and to development of a number of next-generation ophthalmology products.”

- END -
For further information please contact:

<table>
<thead>
<tr>
<th>ThromboGenics</th>
<th>Citigate Dewe Rogerson</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wouter Piepers,</td>
<td>David Dible/Sylvie Berrebi</td>
</tr>
<tr>
<td>Global Head of Corporate Communications &amp; IR</td>
<td>Tel: +44 20 7282 9571</td>
</tr>
<tr>
<td>+32 16 75 13 10 / +32 478 33 56 32</td>
<td><a href="mailto:david.dible@citigatedr.co.uk">david.dible@citigatedr.co.uk</a></td>
</tr>
<tr>
<td><a href="mailto:wouter.piepers@thrombogenics.com">wouter.piepers@thrombogenics.com</a></td>
<td><a href="mailto:sylvie.berrebi@citigatedr.co.uk">sylvie.berrebi@citigatedr.co.uk</a></td>
</tr>
</tbody>
</table>

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. ThromboGenics pioneered the new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is approved for treatment of vitreomacular traction in 54 countries worldwide. The company’s pipeline of disease modifying drug candidates (THR-409, THR-317, THR-149, THR-687) targets all key segments of the diabetic eye disease market: diabetic retinopathy (DR, NPDR, PDR) and/or diabetic macular edema (DME). ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.